#France #Marseille #Terumo Neuro #Aneurysm Treatment #EMEA Alliance

Terumo Neuro Launches Aneurysm Treatment Alliance in EMEA

On September 3, 2025, Terumo Neuro, a prominent name in neurovascular innovation and a subsidiary of Terumo Corporation, unveiled the Aneurysm Treatment Alliance at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) Annual Congress in Marseille, France. This initiative aims to enhance collaboration among physicians and streamline the treatment of aneurysms across the Europe, Middle East, and Africa (EMEA) regions.

The Aneurysm Treatment Alliance is a strategic effort designed to engage healthcare professionals by providing standardized tools and fostering a collaborative platform. With this initiative, Terumo Neuro is committed to showcasing its comprehensive hemorrhagic portfolio, which includes advanced devices and solutions aimed at improving patient care.

Objectives of the Aneurysm Treatment Alliance

The goals of the Aneurysm Treatment Alliance are multifaceted:

1. Comprehensive Portfolio Access

Participants in the alliance will gain access to Terumo Neuro's extensive product range, including the WEB™ Device, LVIS™ EVO™ Stent, FRED™ X Flow Diverter, Hydrogel Coils, and Bare Platinum Coils. These products represent cutting-edge solutions for treating various types of aneurysms, ensuring physicians have the best resources at their disposal.

2. Enhanced Collaboration

The initiative emphasizes a collaborative approach, aiming to deepen physician engagement beyond traditional presentations. By fostering an environment of shared expertise and dialogue, the alliance encourages cross-regional perspectives, enhancing clinical practices and education.

3. Cross-Regional Learnings

One of the key components of the alliance is the exchange of insights and best practices among physicians across the EMEA region. This initiative seeks to improve the quality and consistency of care, reinforcing the commitment to patient outcomes.

4. Opportunities for Cross-Collaboration

By promoting awareness and education regarding integrated implantable device solutions for aneurysm therapy, the alliance opens doors for broader collaboration between different regions and specialties within the field.

Commitment to Innovation and Patient Outcomes

Sebastien Chabeauti, Vice President and General Manager of Terumo Neuro in EMEA, expressed that the company's hemorrhagic portfolio is at the forefront of providing innovative solutions backed by strong clinical outcomes. With the launch of the Aneurysm Treatment Alliance, Terumo Neuro aims to empower physicians with practical tools and opportunities that ultimately enhance the efficacy of aneurysm treatment practices.

This initiative illustrates Terumo Neuro's unwavering commitment to physician partnerships, relentless innovation, and striving to enhance patient outcomes on a global scale.

About Terumo Neuro

Founded in 1997 and acquired by Terumo Corporation in 2006, Terumo Neuro focuses on redefining neurovascular treatment with over thirty products aimed at cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro operates in over seventy countries, supported by a dedicated sales organization and strategic distribution partnerships.

For further information on their products and initiatives, please visit Terumo Neuro's official website. Terumo Corporation, a leader in medical technology for more than a century, employs over 30,000 associates globally, providing innovative solutions in over 160 countries and regions.